-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)
StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)
StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Monday. The brokerage issued a sell rating on the biotechnology company's stock.
Bellerophon Therapeutics Price Performance
BLPH stock opened at $1.03 on Monday. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.41. Bellerophon Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $4.49. The stock has a market capitalization of $9.83 million, a PE ratio of -0.53 and a beta of -0.07.
Get Bellerophon Therapeutics alerts:Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last posted its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.18. As a group, equities analysts expect that Bellerophon Therapeutics will post -2.21 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. Sepio Capital LP bought a new stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 23,800 shares of the biotechnology company's stock, valued at approximately $29,000. Sepio Capital LP owned about 0.25% of Bellerophon Therapeutics as of its most recent filing with the SEC. Hedge funds and other institutional investors own 11.92% of the company's stock.About Bellerophon Therapeutics
(Get Rating)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Featured Articles
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Monday. The brokerage issued a sell rating on the biotechnology company's stock.
斯托克新聞網在週一發佈的一份報告中啟動了對貝勒羅芬治療公司(納斯達克：BLPH-GET評級)股票的報道。該經紀公司對這家生物技術公司的股票發佈了賣出評級。
Bellerophon Therapeutics Price Performance
貝勒羅芬治療藥物的價格表現
BLPH stock opened at $1.03 on Monday. The company has a 50 day moving average price of $1.32 and a 200 day moving average price of $1.41. Bellerophon Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $4.49. The stock has a market capitalization of $9.83 million, a PE ratio of -0.53 and a beta of -0.07.
週一，BLPH的股票開盤報1.03美元。該公司的50日移動均線價格為1.32美元，200日移動均線價格為1.41美元。貝勒羅芬治療公司的股價為0.67美元，為52周低點，52周高點為4.49美元。該股市值為983萬美元，市盈率為-0.53，貝塔係數為-0.07。
Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) last posted its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.18. As a group, equities analysts expect that Bellerophon Therapeutics will post -2.21 earnings per share for the current fiscal year.
貝勒羅芬治療公司(納斯達克：BLPH-GET Rating)上一次公佈季度收益數據是在8月15日(星期一)。這家生物技術公司公佈了本季度每股收益(0.43美元)，比普遍預期的(0.61美元)高出0.18美元。股票分析師預計，貝勒羅芬治療公司本財年的每股收益將達到2.21美元。
Institutional Inflows and Outflows
機構資金流入和流出
About Bellerophon Therapeutics
關於貝勒羅芬治療公司
(Get Rating)
(獲取評級)
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
貝勒羅芬治療公司是一家臨牀階段治療公司，專注於在美國開發治療心肺疾病的產品。其產品包括INOPulse，這是一種用於治療肺動脈高壓的專有脈衝式一氧化氮輸送平臺。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Bellerophon Therapeutics (BLPH)
- Humana Proves Vertically Integrated Healthcare Works
- What Cintas Can Teach Investors About This Bear Market?
- 2 Casino Stocks Worth Taking a Look At
- This Small-Cap Healthcare Name Is Outperforming Its Index
- Blackberry Stock Declines As Results Come In Lukewarm Once Again
- 免費獲取StockNews.com關於貝勒羅芬治療(BLPH)的研究報告
- Humana證明垂直整合的醫療保健工作
- 關於這個熊市，Cintas能教給投資者什麼？
- 值得一看的2只賭場股票
- 這家小盤股醫療保健公司的表現好於其指數
- 黑莓股價下跌，業績再次不温不火
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受貝勒羅芬治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bellerophon治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧